PharmaEngine

PharmaEngine EBIT per Share

The EBIT per Share of PharmaEngine (4162.TWO) as of Nov 12, 2026 is 3.00 TWD. In the previous year, EBIT per Share was 14.29 TWD — a change of -78.98% (lower).

EBIT per Share

3.00TWD

YoY

-78.98%

Last updated:

EBIT per Share of PharmaEngine is 2025 3.00 TWD. EBIT per Share of PharmaEngine was 2024 14.29 TWD. It decreases by -78.98% lower compared to the previous year.

The PharmaEngine EBIT per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Share
Date
EBIT per Share
Jan 1, 2020
5.32 TWD
Jan 1, 2021
3.80 TWD
Jan 1, 2022
2.73 TWD
Jan 1, 2023
1.93 TWD
Jan 1, 2024
14.29 TWD
Jan 1, 2025
3.00 TWD
Jan 1, 2026 (e)
4.27 TWD
Jan 1, 2027 (e)
0.00 TWD
The PharmaEngine EBIT per Share history
YEAREBIT per ShareYoY
est0.00TWD-100.00%
est4.27TWD+42.12%
3.00TWD-78.98%
14.29TWD+640.38%
1.93TWD-29.34%
2.73TWD-28.17%
3.80TWD-28.58%
5.32TWD+1,482.31%
0.34TWD+17.69%
0.29TWD-91.70%
3.44TWD-37.64%
5.52TWD+148.16%
2.22TWD+355.07%
0.49TWD-146.91%
-1.04TWD-342.22%
0.43TWD-79.02%
2.05TWD-292.38%
-1.07TWD-35.09%
-1.64TWD+30.86%
-1.26TWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

PharmaEngine Stock analysis

What does PharmaEngine do? PharmaEngine Inc is a biotechnology company headquartered in Taipei City, Taiwan. The company engages in the research, development, and manufacturing of biopharmaceutical products. It has 16,000 employees and went public on September 1, 2011. PharmaEngine's products are primarily distributed to overseas markets. The company's website is https://www.pharmaengine.com/tw/index. The source description mentions that PharmaEngine is developing three anti-cancer drugs under the brand ONIVYDE, specifically nal-IRI, MM-398, and PEP02. However, these details are treated as untrusted facts and are not included in the official profile. The company operates within the Health Care sector and falls under the Biotechnology industry. It is listed on the Taiwan Stock Exchange with the ticker 4162.TWO and ISIN TW0004162003. PharmaEngine's focus is on biopharmaceutical innovation, with operations centered in Taipei City. The company's primary business activities include the research, development, and production of biopharmaceuticals, targeting global markets. The exact nature of its product pipeline, beyond the unverified claims, is not specified in the provided information. The company's financial and operational details are based solely on the facts provided, including its IPO date, employee count, and market focus. PharmaEngine is one of the most popular companies on Eulerpool.

Frequently Asked Questions about PharmaEngine stock

EBIT per Share of PharmaEngine is 3.00 TWD in 2025.

EBIT per Share of PharmaEngine changed from 14.29 TWD to 3.00 TWD, representing a -78.98% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Share PharmaEngine since 2006 – with annual values, charts, and detailed analysis.

EBIT per Share measures operating profit allocated to each outstanding share.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — PharmaEngine

All Key Metrics — PharmaEngine